BioNTech raises $325M in Series B round, skipping IPO for now
The News: Germany’s BioNTech raises eye-popping €290M ($325M) in Series B round to fund personalized mRNA cancer vaccines, eschewing IPO for now. Just where does German biotech stand vis-à-vis the… Read more »